FDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerThe FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated Share XFDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerhttps://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaa-combo-in-advanced-colorectal-cancer/
Patient Insights: Colorectal CancerEvent planner and colorectal cancer survivor Kim Hall-Jackson tells us how she hopes to improve rates of diagnosis, Share XPatient Insights: Colorectal Cancerhttps://pharmaphorum.com/views-analysis-patients/patient-insights-colorectal-cancer/
ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengeAmgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported Share XESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengehttps://pharmaphorum.com/news/esmo-2019-amgens-kras-drug-finds-colorectal-cancer-a-challenge/
Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’A new trial has shown for the first time that a combination of three targeted therapies can improve Share XArray, Pierre Fabre bowel cancer therapy ‘could replace chemo’https://pharmaphorum.com/news/array-pierre-fabre-bowel-cancer-therapy-could-replace-chemo/
FDA approves consumer colorectal cancer testThe FDA will allow consumer DNA testing company 23andMe to give customers reports on their risk of hereditary Share XFDA approves consumer colorectal cancer testhttps://pharmaphorum.com/news/fda-approves-consumer-colorectal-cancer-test/
BMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientsBristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal Share XBMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientshttps://pharmaphorum.com/news/bms-opdivoyervoy-could-become-first-choice-for-certain-colorectal-cancer-patients/
BMS immunotherapy combo approved in new colorectal useBristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients Share XBMS immunotherapy combo approved in new colorectal usehttps://pharmaphorum.com/news/bms-immunotherapy-combo-approved-in-new-colorectal-use/
